QUANTI Pediatric assessed the pharmacokinetics and safety of gadoquatrane in children from birth to < 18 years of age undergoing contrast-enhanced MRI. The design and dosing of the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback